HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Asymchem Laboratories (002821.CH) 2021H1 Results - Not Good Enough

Pharmaron Beijing Co Ltd (3759.HK) 2021Q3 - Still Takes Time to Challenge Wuxi AppTec

Hangzhou Tigermed Consulting (3347.HK/300347.CH) - More of an Investment Company than a CRO

Pre-IPO Asymchem Laboratories - The Strength and the Concerns

Pre-IPO Novotech Holdings - The Future Would Not Be Easy

WuXi AppTec (2359.HK) - The Certainties and the Uncertainties

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Ambio Pharmaceuticals / Equity Capital Markets

<p>On June 25, 2021, <a href="https://www.smartkarma.com/entities/ambio-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:33696:1" rel="noopener">Ambio Pharmaceuticals (ABP HK)</a> filed a prospectus with the HKEX and officially started its IPO process. Ambio is a leading peptide CDMO and also the fourth largest peptide CDMO service provider globally in terms of revenue in 2020. This insight mainly analyzed the industry characteristics, the business and the concerns of the Company.</p>

On June 25, 2021, Ambio Pharmaceuticals (ABP HK) filed a prospectus with the HKEX and officially started its IPO process. Ambio is a leading peptide CDMO and also the fourth largest peptide CDMO service provider globally in terms of revenue in 2020. This insight mainly analyzed the industry characteristics, the business and the concerns of the Company.

Asymchem Laboratories Tianjin (002821 CH)

Pre-IPO Ambio Pharmaceuticals - The Particularity of Peptide Drugs, the Strength and the Concerns